Hormonal
Obesity is a chronic, highly heritable neurological disease driven by central nervous system regulation of satiety and reward, rather than solely a behavioral failure of willpower.
Obesity is a biological condition involving brain pathways that control hunger and reward, heavily influenced by genetics. This means it is not simply a failure of willpower. Effective management often requires addressing these biological drivers, potentially through medical therapies that target these specific pathways, rather than relying solely on lifestyle changes which may be insufficient for those with high genetic risk.
Obesity is a highly prevalent chronic disease... Obesity is also a heritable neuronal disease with heritability estimates of up to 70%.
Why this rating
Based on large-scale genetic studies, Mendelian randomization, and clinical trials of targeted therapies.
Source
Obesity and Cardiometabolic Disease: Insights From Genetic Studies
Satya Dash · Canadian Journal of Cardiology · 2025
DOI 10.1016/j.cjca.2025.01.034
More from this paper
- Increased BMI causally increases the risk of coronary artery disease and heart failure, independent of traditional risk factors like blood pressure and diabetes, though these factors mediate a significant portion of the risk.Strong
- Central adiposity (measured by waist-to-hip ratio) is a stronger predictor of cardiometabolic risk than overall body mass index (BMI), primarily due to visceral fat and limited subcutaneous storage capacity leading to ectopic lipid deposition.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →